Literature DB >> 16019262

Anti-myeloperoxidase IgG subclass distribution and avidity in sera from patients with propylthiouracil-induced antineutrophil cytoplasmic antibodies associated vasculitis.

Ying Gao1, Hua Ye, Feng Yu, Xiao-Hui Guo, Ming-Hui Zhao.   

Abstract

OBJECTIVE: Propylthiouracil (PTU) could induce MPO-ANCA-positive vasculitis. The aim of this study was to compare the IgG subclass distribution and avidity of MPO-ANCA in sera from patients with primary ANCA-associated vasculitis (AASV) and PTU-induced vasculitis.
METHODS: Nineteen patients with primary AASV with MPO-ANCA and thirteen patients with PTU-induced vasculitis were enrolled in the current study. Sera in both active phase and remission were collected. Anti-MPO IgG subclasses were detected by antigen specific ELISAs using specific monoclonal antibodies as second antibodies, and MPO-ANCA avidity was assessed by antigen-inhibition ELISAs.
RESULTS: In primary AASV, all four anti-MPO IgG subclasses could be detected in active phase with IgG1 (100%), IgG2 (73.7%), IgG3 (63.2%) and IgG4 (94.7%), and in remission, IgG1 and IgG4 subclasses in most patients remained positive. However, in PTU-induced vasculitis, anti-MPO IgG3 subclass could not be detected, the anti-MPO IgG subclasses in active phase were IgG1 (100%), IgG2 (61.5%) and IgG4 (46.2%). Furthermore, five out of the six patients (88.8%) with PTU-induced vasculitis with positive IgG4 subclass in active phase turned to negative in remission, however, only eight out of the fourteen patients (57.1%) with primary AASV turned to negative. The median avidity constant of MPO-ANCA was 56 (8.96 to >140) x 10(7) mol/l for patients with primary AASV and 0.7 (<0.28 to >140) x 10(7) mol/l for patients with PTU-induced vasculitis respectively. Furthermore, the relative levels of MPO-ANCA avidity were associated with elevation of ESR in primary AASV and were associated with BVAS scores in patients with PTU-induced vasculitis, respectively.
CONCLUSION: MPO-ANCA IgG subclass distribution and avidity were different between patients with primary AASV and PTU-induced vasculitis. It was suggested that the mechanism of ANCA production in PTU-induced vasculitis was different from that in primary AASV, and the avidity of MPO-ANCA might be associated with disease activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16019262     DOI: 10.1016/j.clim.2005.06.002

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  6 in total

Review 1.  Propylthiouracil-induced antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Min Chen; Ying Gao; Xiao-Hui Guo; Ming-Hui Zhao
Journal:  Nat Rev Nephrol       Date:  2012-06-05       Impact factor: 28.314

Review 2.  Antineutrophil cytoplasmic autoantibody-associated vasculitis in Chinese patients.

Authors:  Peng-Cheng Xu; Min Chen; Ming-Hui Zhao
Journal:  Clin Exp Nephrol       Date:  2012-11-23       Impact factor: 2.801

Review 3.  The Prevalence and Management of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis in China.

Authors:  Zhi-Ying Li; Tian-Tian Ma; Min Chen; Ming-Hui Zhao
Journal:  Kidney Dis (Basel)       Date:  2015-12-09

4.  Anti-Nuclear Cytoplasmic Antibody-Associated Vasculitis: A Probable Adverse Effect of Sofosbuvir Treatment in Chronic Hepatitis C Patients.

Authors:  Youssef K Ahmad; Salwa Tawfeek; Mohamed Sharaf-Eldin; Hassan E Elbatea; Abdelrahman Kobtan; Ferial El-Kalla; Rehab Badawi; Sherief Abd-Elsalam
Journal:  Hosp Pharm       Date:  2017-04

5.  Screening for IgG4-type anti-nuclear antibodies in IgG4-related disease.

Authors:  Kazuhiro Kiyama; Hajime Yoshifuji; Tsugumitsu Kandou; Yuji Hosono; Koji Kitagori; Ran Nakashima; Yoshitaka Imura; Naoichiro Yukawa; Koichiro Ohmura; Takao Fujii; Daisuke Kawabata; Tsuneyo Mimori
Journal:  BMC Musculoskelet Disord       Date:  2015-05-28       Impact factor: 2.362

6.  Epitope analysis of anti-myeloperoxidase antibodies in propylthiouracil-induced antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Chen Wang; Shen-ju Gou; Peng-cheng Xu; Ming-hui Zhao; Min Chen
Journal:  Arthritis Res Ther       Date:  2013       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.